PharmAla Biotech Holdings Inc. will supply the University of Texas, San Antonio, with LaNeo™ MDMA for a proposed clinical trial. The collaboration aims to create and test a novel dosage form of LaNeo™ MDMA in an investigator-initiated human clinical trial.
Supporting Innovative Research
Nicholas Kadysh, CEO of PharmAla Biotech, stated the company is prepared to support researchers with its existing API and 40mg capsules, as well as in the development of new dosage forms for LaNeo™ MDMA. He noted that while the current 40mg dose is suitable for many assisted therapy use-cases, PharmAla is open to partnering with researchers exploring different doses and drug delivery models.
Patent Publication
PharmAla also announced the publication of a patent application by the USPTO related to the potential uses of PharmAla’s APA-01 novel molecular entity. This application is a divisional application arising from PharmAla’s original APA-01 patent, which was granted earlier this year as US Patent #12,042,428.
Dr. Harpreet Kaur, VP of Research at PharmAla Biotech, thanked IPON for their support in the company's global patent filings. She emphasized the importance of keeping this valuable IP in Canada.
